These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 16185866)

  • 1. Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11beta-HSD1: novel therapeutic agents for the treatment of metabolic syndrome.
    Gu X; Dragovic J; Koo GC; Koprak SL; LeGrand C; Mundt SS; Shah K; Springer MS; Tan EY; Thieringer R; Hermanowski-Vosatka A; Zokian HJ; Balkovec JM; Waddell ST
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5266-9. PubMed ID: 16185866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bis-aryl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
    Aster SD; Graham DW; Kharbanda D; Patel G; Ponpipom M; Santorelli GM; Szymonifka MJ; Mundt SS; Shah K; Springer MS; Thieringer R; Hermanowski-Vosatka A; Wright SD; Xiao J; Zokian H; Balkovec JM
    Bioorg Med Chem Lett; 2008 May; 18(9):2799-804. PubMed ID: 18434143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adamantyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
    Olson S; Aster SD; Brown K; Carbin L; Graham DW; Hermanowski-Vosatka A; LeGrand CB; Mundt SS; Robbins MA; Schaeffer JM; Slossberg LH; Szymonifka MJ; Thieringer R; Wright SD; Balkovec JM
    Bioorg Med Chem Lett; 2005 Oct; 15(19):4359-62. PubMed ID: 16039856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of potent and selective inhibitors of 11beta-HSD1 for the treatment of metabolic syndrome.
    Richards S; Sorensen B; Jae HS; Winn M; Chen Y; Wang J; Fung S; Monzon K; Frevert EU; Jacobson P; Sham H; Link JT
    Bioorg Med Chem Lett; 2006 Dec; 16(24):6241-5. PubMed ID: 17000111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bicyclo[2.2.2]octyltriazole inhibitors of 11β-hydoxysteroid dehydrogenase type 1. Pharmacological agents for the treatment of metabolic syndrome.
    Maletic M; Leeman A; Szymonifka M; Mundt SS; Zokian HJ; Shah K; Dragovic J; Lyons K; Thieringer R; Vosatka AH; Balkovec J; Waddell ST
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2568-72. PubMed ID: 21421311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substituted phenyl triazoles as selective inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1.
    Sun W; Maletic M; Mundt SS; Shah K; Zokian H; Lyons K; Waddell ST; Balkovec J
    Bioorg Med Chem Lett; 2011 Apr; 21(7):2141-5. PubMed ID: 21334894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
    Schnackenberg CG
    Curr Opin Investig Drugs; 2008 Mar; 9(3):295-300. PubMed ID: 18311666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling.
    Yang H; Dou W; Lou J; Leng Y; Shen J
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1340-5. PubMed ID: 18242087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diazepane-acetamide derivatives as selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors.
    Odermatt A
    Expert Opin Ther Pat; 2009 Oct; 19(10):1477-83. PubMed ID: 19780703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of orally active butyrolactam 11beta-HSD1 inhibitors.
    Yeh VS; Kurukulasuriya R; Fung S; Monzon K; Chiou W; Wang J; Stolarik D; Imade H; Shapiro R; Knourek-Segel V; Bush E; Wilcox D; Nguyen PT; Brune M; Jacobson P; Link JT
    Bioorg Med Chem Lett; 2006 Nov; 16(21):5555-60. PubMed ID: 16931002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenylcyclobutyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I.
    Zhu Y; Olson SH; Graham D; Patel G; Hermanowski-Vosatka A; Mundt S; Shah K; Springer M; Thieringer R; Wright S; Xiao J; Zokian H; Dragovic J; Balkovec JM
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3412-6. PubMed ID: 18440812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of 11beta-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role?
    Thieringer R; Hermanowski-Vosatka A
    Expert Rev Cardiovasc Ther; 2005 Sep; 3(5):911-24. PubMed ID: 16181035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and structure-activity relationships of pentanedioic acid diamides as potent inhibitors of 11beta-hydroxysteroid dehydrogenase type I.
    Roche D; Carniato D; Leriche C; Lepifre F; Christmann-Franck S; Graedler U; Charon C; Bozec S; Doare L; Schmidlin F; Lecomte M; Valeur E
    Bioorg Med Chem Lett; 2009 May; 19(10):2674-8. PubMed ID: 19395260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-Methyl-5-phenyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I.
    Zhu Y; Olson SH; Hermanowski-Vosatka A; Mundt S; Shah K; Springer M; Thieringer R; Wright S; Xiao J; Zokian H; Balkovec JM
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3405-11. PubMed ID: 18440811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
    Johansson L; Fotsch C; Bartberger MD; Castro VM; Chen M; Emery M; Gustafsson S; Hale C; Hickman D; Homan E; Jordan SR; Komorowski R; Li A; McRae K; Moniz G; Matsumoto G; Orihuela C; Palm G; Veniant M; Wang M; Williams M; Zhang J
    J Med Chem; 2008 May; 51(10):2933-43. PubMed ID: 18419108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azabicyclic sulfonamides as potent 11beta-HSD1 inhibitors.
    Shah U; Boyle CD; Chackalamannil S; Baker H; Kowalski T; Lee J; Terracina G; Zhang L
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1551-4. PubMed ID: 20149650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents.
    Boyle CD; Kowalski TJ
    Expert Opin Ther Pat; 2009 Jun; 19(6):801-25. PubMed ID: 19456274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel, potent benzamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) exhibiting oral activity in an enzyme inhibition ex vivo model.
    Julian LD; Wang Z; Bostick T; Caille S; Choi R; DeGraffenreid M; Di Y; He X; Hungate RW; Jaen JC; Liu J; Monshouwer M; McMinn D; Rew Y; Sudom A; Sun D; Tu H; Ursu S; Walker N; Yan X; Ye Q; Powers JP
    J Med Chem; 2008 Jul; 51(13):3953-60. PubMed ID: 18553955
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The discovery of azepane sulfonamides as potent 11beta-HSD1 inhibitors.
    Neelamkavil SF; Boyle CD; Chackalamannil S; Greenlee WJ; Zhang L; Terracina G
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4563-5. PubMed ID: 19625185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of sulfonamidooxazoles and beta-keto sulfones: selective inhibitors of 11beta-hydroxysteroid dehydrogenase type I.
    Xiang J; Ipek M; Suri V; Massefski W; Pan N; Ge Y; Tam M; Xing Y; Tobin JF; Xu X; Tam S
    Bioorg Med Chem Lett; 2005 Jun; 15(11):2865-9. PubMed ID: 15911270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.